Sign in
Taking peopleNo phase

Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study

Key facts

Who runs it
Sichuan Provincial People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
11 Nov 2025
Expected to end
11 Nov 2027
Type of study
Observational, 2 groups
Treatments tested
  • Sulbactam-Durlobactam
Record updated
22 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age ≥18 years
  • Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:; patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or; transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy
  • Treatment initiation time can be clearly determined
  • Availability of clinical outcome data

Who cannot take part

  • Colonization without evidence of active infection
  • Missing key clinical data
  • Inability to determine treatment initiation time
  • Pregnancy or lactation
  • Patients considered unsuitable by investigators

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.

Read full original descriptionShow less

The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.

To reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.

The 2 groups in the trial

  • Sulbactam-Durlobactam Group

    Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.

    Treatment: Sulbactam-Durlobactam

  • Non-Sulbactam-Durlobactam Group

    Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis
Criteria questions
Built from NCT07601711, who can take part
Record updated
22 May 2026